Target intelligence / Profile preview

Diphtheria Toxin Mutant Protein Carrier (CRM197) (CRM197)

Target
CRM197
Molecular classification
Toxin, Mutant Protein, Carrier Protein
01

Overview

CRM197 is a genetically detoxified mutant of diphtheria toxin, specifically modified at position 52 (G52E). It serves as a carrier protein in conjugate vaccines, enhancing the immunogenicity of polysaccharides and haptens. It facilitates T-cell dependent immune responses and is a key component of vaccines against encapsulated bacteria like Streptococcus pneumoniae, Haemophilus influenzae type b, and Neisseria meningitidis. While retaining the structure and immunological properties of the native toxin, the mutation renders it non-toxic. It has also been investigated experimentally as a potential inhibitor of HB-EGF in cancer research.

Other names
Corynebacterium diphtheriae CRM197 proteinCross-Reactive Material 197
02

Mechanism of action

CRM197, when conjugated to poorly immunogenic antigens like polysaccharides, facilitates their presentation to T cells, converting a T-cell independent response to a T-cell dependent one, resulting in enhanced antibody production and immunological memory.

03

Biological functions

Carrier for conjugate vaccinesEnhances immunogenicity of polysaccharides and haptensInduces T-cell dependent immune responses
04

Disease associations

Infection (prevention through vaccination)
05

Safety considerations

Potential toxicity in some cell lines (in vitro studies)Carrier-induced suppression in multivalent vaccines (less than other carriers)
06

Interacting drugs

Prevnar

3 more in the full profile.

Beyond the preview

Go deeper on Diphtheria Toxin Mutant Protein Carrier (CRM197) (CRM197).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diphtheria Toxin Mutant Protein Carrier (CRM197) (CRM197).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call